What Will Drive Korean Pharma's Next Decade Of Growth?
Ample Pipelines, Direct Global Entry May Be Key
A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth
You may also be interested in...
Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.